α-PiHP (Alpha-Pyrrolidinoisohexanophenone): Complete Human Pharmacology, Fatality & Dependence Monograph

α-PiHP: Complete Human Pharmacology, Fatality & Dependence Monograph

Emergency stimulant toxicity: Severe agitation/confusion, seizure, dangerous overheating, chest pain, collapse, very fast or irregular heartbeat, loss of consciousness, or behavior that cannot be safely controlled after an unknown stimulant requires urgent medical care.

Quick answer

α-PiHP is alpha-pyrrolidinoisohexanophenone, a potent pyrrolidinophenone stimulant and positional isomer of α-PHP.

Its evidence base is now unusually strong for a modern synthetic cathinone.

It includes:

• direct human observational pharmacology;
• human DAT/NET data;
• authentic human metabolism;
• routine forensic plasma cases;
• a primary-cause fatality;
• broad postmortem distribution;
• a 2026 forensic series showing substantial concentration overlap between fatal and nonfatal contexts.

The central toxicology lesson is that α-PiHP can be highly reinforcing and medically dangerous while blood concentration remains a poor standalone predictor of outcome.

Identity

History and market evolution

α-PiHP was first reported to European drug-monitoring authorities in 2016.

It then grew rapidly as earlier pyrovalerones such as α-PVP and α-PHP were increasingly controlled.

By 2022–2023, α-PiHP had become one of the most prominent seized pyrovalerone cathinones in Europe.

Its rise also produced a major analytical problem because α-PiHP and α-PHP have:

• the same molecular formula;
• very similar mass spectra;
• different carbon-chain branching.

Pharmacology

Dopamine and norepinephrine transporters

Direct experimental studies show α-PiHP is a potent inhibitor of:

• DAT;
• NET;

with substantially weaker serotonergic-transporter activity.

This creates a strongly stimulant/catecholaminergic profile.

Comparison with α-PVP

A 2025 translational study found α-PiHP had DAT inhibition comparable to α-PVP in the experimental system, with somewhat lower NET potency.

Animal PK/behavior differed, demonstrating why transporter potency should not be converted into a human dose ratio.

2026 human observational pharmacology

A 2026 naturalistic study examined 17 healthy adults with previous psychostimulant experience under monitored conditions.

Compared with cocaine, α-PiHP produced:

• rapid absorption;
• increased heart rate;
• more sustained blood-pressure elevation;
• classic psychostimulant subjective effects;
• measurable distribution into oral fluid, urine, sweat and dried blood spots.

The study estimated a short elimination half-life in this selected sample.

Why the half-life is not a redosing clock

The study was:

• small;
• non-controlled;
• naturalistic;
• limited to experienced, screened participants.

Its PK estimate should not be generalized to:

• binge use;
• unknown street products;
• cardiovascular disease;
• polysubstance exposure.

Human forensic plasma evidence

A 2024 study compared α-PHP and α-PiHP in routine forensic cases.

α-PiHP was found in authentic human plasma, with behavioral/context data.

Real-world findings reinforce that α-PiHP occurs frequently with other psychoactive substances, which complicates symptom attribution.

Fatal α-PiHP intoxication

A published forensic case concluded that fatal α-PiHP intoxication was the cause of death based on:

• scene investigation;
• autopsy;
• histopathology;
• toxicology.

α-PiHP and hydroxy-α-PiHP were measured across a very wide range of tissues and fluids.

This establishes intrinsic lethal potential.

Postmortem distribution

The fatality study detected α-PiHP in:

• heart and femoral blood;
• dural venous blood;
• vitreous humor;
• cerebrospinal fluid;
• multiple brain regions;
• liver;
• kidney;
• lung;
• bile;
• gastrointestinal contents;
• adipose tissue.

This broad distribution is useful for forensic interpretation but cannot define a universal fatal concentration.

2026 forensic concentration series

A 2026 case series used a validated method capable of separating:

• α-PHP;
• α-PiHP;
• MDPHP;
• MDPiHP.

For α-PiHP, postmortem blood concentrations ranged from approximately 0.3 to 840 ng/mL.

The study emphasized considerable overlap between intoxication and fatal exposures.

Meaning

A blood result can support exposure and contextual interpretation.

It cannot, by itself, answer:

• how much was used;
• whether the person was impaired at a specific level;
• whether death was inevitable.

Acute stimulant toxicity

Severe α-PiHP toxicity can plausibly and clinically involve:

• agitation;
• panic;
• paranoia;
• hallucinations;
• stimulant-induced psychosis;
• tachycardia;
• hypertension;
• chest pain;
• hyperthermia;
• seizures;
• rhabdomyolysis;
• cardiovascular collapse.

Direct human studies are not large enough to estimate incidence for each outcome.

Cardiovascular risk

The 2026 human study directly documented:

• heart-rate increase;
• sustained blood-pressure elevation.

Pyrrolidinophenone toxicity can also involve arrhythmia and cardiac stress.

There is no validated concentration at which cardiovascular risk becomes safe or unsafe for every person.

Psychiatric toxicity

α-PiHP belongs to a class strongly associated with:

• paranoia;
• repetitive behavior;
• severe agitation;
• psychosis.

Sleep deprivation and compulsive redosing can amplify these effects.

Hyperthermia and rhabdomyolysis

Potent stimulant exposure can combine:

• adrenergic activation;
• prolonged activity;
• dehydration;
• environmental heat.

That combination can produce hyperthermia and secondary muscle/kidney injury.

Human metabolism

A 2023 human-metabolism study used:

• pooled human liver microsomes;
• S9 fraction;
• authentic user urine.

Ten urinary metabolites were identified.

Major products involved:

• keto reduction;
• pyrrolidine-ring oxidation;
• aliphatic hydroxylation;
• ring opening with carboxylation;
• glucuronidation.

Several metabolites were more abundant in urine than parent α-PiHP.

Biomarkers

Useful targets include:

• parent α-PiHP;
• keto-reduced metabolites;
• oxidized/ring-opened metabolites.

Metabolite-aware testing can improve exposure confirmation beyond parent-only screening.

α-PiHP vs α-PHP: the isomer problem

Because α-PiHP and α-PHP are structural isomers, laboratories need adequate chromatographic separation.

A 2024 study used:

• metabolic differences;
• retention times;
• high-resolution mass spectra;
• machine-learning classification

to improve differentiation.

The 2026 forensic series reinforced the same principle.

Reporting rule

If the method cannot separate the isomers, the report should disclose that uncertainty rather than assign one with false precision.

Drug testing

Routine immunoassays

Routine amphetamine/cocaine immunoassays do not specifically identify α-PiHP.

A negative routine screen does not rule it out.

Definitive testing

Useful methods include:

• LC-MS/MS;
• LC-QTOF-MS;
• LC-HRMS;
• parent/metabolite targets;
• isomer-resolving chromatography.

Interactions

No controlled α-PiHP interaction map defines safe combinations.

Important high-risk contexts include:

• other stimulants;
• MAO inhibitors;
• alcohol/benzodiazepines masking warning signs;
• opioids causing independent respiratory depression;
• other pyrrolidinophenones increasing stimulant load.

Polysubstance exposure is common in forensic casework.

Tolerance

Repeated stimulant exposure can produce tolerance.

There is no validated α-PiHP tolerance timeline.

Reduced subjective stimulation does not prove tolerance to:

• blood-pressure effects;
• hyperthermia;
• psychosis;
• seizures;
• arrhythmia.

Dependence and stimulant use disorder

α-PiHP's:

• DAT/NET potency;
• high stimulant/reward signal in animal models;
• rapid human subjective effects

support substantial abuse liability.

WHO concluded its dependence potential was expected to resemble other powerful psychostimulants.

Human incidence remains unquantified.

Warning signs include:

• craving;
• compulsive redosing;
• prolonged binges;
• inability to cut down;
• continued use despite harm.

Stimulant withdrawal

After sustained use, stimulant withdrawal can include:

• profound fatigue;
• hypersomnia or insomnia;
• depressed mood;
• anhedonia;
• irritability;
• slowed thinking;
• increased appetite;
• craving.

There is no α-PiHP-specific validated withdrawal timeline.

Severe depression, suicidality or persistent psychosis warrants urgent clinical care.

Treatment and support

There is no medication approved specifically for α-PiHP use disorder.

The ASAM/AAAP stimulant-use-disorder guideline identifies contingency management as a core evidence-based treatment, often combined with CBT/community reinforcement.

Acute severe intoxication requires complication-directed emergency care.

U.S. resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Forensic interpretation

Concentration overlap is the rule

The 2026 case series directly demonstrates wide overlap between intoxication and fatal concentrations.

Isomer identity must be proven

A concentration attributed to α-PiHP is meaningful only if the method distinguishes α-PHP.

Detection does not equal sole causation

Co-drugs are common and must be incorporated into cause-of-death or impairment interpretation.

Special populations

Controlled α-PiHP data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• seizure disorders;
• psychotic/bipolar disorders;
• liver/kidney disease.

A potent catecholaminergic stimulant deserves particular caution in cardiovascular and psychiatric vulnerability.

Legal status

United States

DEA formally added α-PiHP to the named Schedule I list with drug code 7551, effective December 13, 2023.

DEA explained that α-PiHP had already been federally controlled as a positional isomer of α-PHP.

International

The UN Commission on Narcotic Drugs placed α-PiHP in Schedule II of the 1971 Convention on Psychotropic Substances.

That decision entered into force November 13, 2023.

Myths and misconceptions

"α-PiHP is just α-PHP with a different spelling."
False. They are structural isomers.

"The 2026 human half-life tells you when it is safe to redose or drive."
False. It came from a small selected observational sample and does not define functional recovery.

"A fatal blood concentration gives the lethal dose."
False. Fatal and nonfatal concentrations overlap.

"A negative amphetamine screen rules it out."
False.

"Tolerance protects against blood-pressure or psychosis risk."
Not established.

Evidence ledger

Related evidence

• α-PHP
• α-PVP
• MDPiHP
• MDPHP
• N-Ethylhexedrone
• Synthetic cathinones & RC stimulants
• Substance Use, Dependence & Harm Reduction hub

Bottom line

α-PiHP now has one of the stronger evidence packages among current pyrrolidinophenone stimulants.

Human observational pharmacology confirms real cardiovascular and subjective stimulant effects; metabolism studies identify useful biomarkers; a fatality establishes intrinsic lethal potential; and modern forensic work shows why blood concentration alone cannot sort intoxication from death.

The key safety message is therefore not a potency ranking.

It is high reinforcement + cardiovascular/psychiatric toxicity + major concentration overlap + the need to prove the correct isomer analytically.